Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-methoxy-2-aminoindane + palmitoylethanolamide
- Development stage
- Unknown
- Lead developer
- Clearmind Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination drug consists of 5-methoxy-2-aminoindane (MEAI), a synthetic aminoindane derivative, and palmitoylethanolamide (PEA), an endogenous fatty acid amide. MEAI acts primarily as a selective serotonin releasing agent (SSRA) and is being investigated for its potential to reduce alcohol consumption by mimicking the pleasurable effects of alcohol without the associated toxicity or impairment. PEA is included in the formulation to potentially enhance the safety profile and provide anti-inflammatory and neuroprotective benefits via its action as a PPAR-alpha agonist. The combination is primarily being developed by Clearmind Medicine for the treatment of Alcohol Use Disorder (AUD) and other addictive behaviors, such as binge eating.
- Other names
- MEAI + PEA5-MeO-AI + PEA
02
Targets
ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)DAT (Dopamine plasma membrane transport protein)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (5-hydroxytryptamine receptor 2A)HTR2B (5-Hydroxytryptamine Receptor 2B)NET (Norepinephrine Transporter)PPARA (Peroxisome proliferator-activated receptor alpha)SERT (Sodium-dependent serotonin transporter)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on 5-methoxy-2-aminoindane + palmitoylethanolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-methoxy-2-aminoindane + palmitoylethanolamide.